GlaxoSmithKline shares are on the mend after years of poor performance as investors feel better about the company’s prospects of replacing one blockbuster asthma drug with another, Jack Hough writes in this week’s edition of Barron’s. Best known for Advair that has been off-patent since 2016 and in decline for longer than that, GlaxoSmithKline has a new drug in Trelegy for asthma and chronic obstructive pulmonary disease, the report noted, adding that the company’s overall respiratory-drug sales are expected to return to growth after next year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.